Hofer BS; Simbrunner B; Königshofer P; Brusilovskaya K; Petrenko O; Taru V; Sorz T; Zinober K; Semmler G; Kauschke SG; Pfisterer L; Trauner M; Mandorfer M; Schwabl P; Reiberger T, 2024. Aetiology-specific inflammation patterns in patients and rat models of compensated cirrhosis. Dig Liver Dis.
Burghart L; Ferenci P; Petrenko O; Mandorfer M; Schwarz M; Gschwantler M; Trauner M; Reiberger T; Stättermayer AF, 2024. Portal hypertension and its prognostic implications in patients with Wilson's disease. Aliment Pharmacol Ther 60(2):257-266
Hofer BS; Burghart L; Halilbasic E; Simbrunner B; Petrenko O; Mandorfer M; Stättermayer AF; Trauner M; Reiberger T, 2024. Editorial: Recompensation in PBC is good. But is it good enough? Authors' reply. Aliment Pharmacol Ther 59(9):1146-1147
Petrenko O; Königshofer P; Brusilovskaya K; Hofer BS; Bareiner K; Simbrunner B; Jühling F; Baumert TF; Lupberger J; Trauner M; Kauschke SG; Pfisterer L; Simon E; Rendeiro AF; de Rooij LPMH; Schwabl P; Reiberger T, 2024. Transcriptomic signatures of progressive and regressive liver fibrosis and portal hypertension. iScience 27(3):109301
Hofer BS; Burghart L; Halilbasic E; Simbrunner B; Petrenko O; Mandorfer M; Stättermayer AF; Trauner M; Reiberger T, 2024. Evaluation of potential hepatic recompensation criteria in patients with PBC and decompensated cirrhosis. Aliment Pharmacol Ther 59(8):962-972
Simbrunner B; Hofer BS; Schwabl P; Zinober K; Petrenko O; Fuchs C; Semmler G; Marculescu R; Mandorfer M; Datz C; Trauner M; Reiberger T, 2024. FXR-FGF19 signaling in the gut-liver axis is dysregulated in patients with cirrhosis and correlates with impaired intestinal defence. Hepatol Int 18(3):929-942
Reiniš J; Petrenko O; Simbrunner B; Hofer BS; Schepis F; Scoppettuolo M; Saltini D; Indulti F; Guasconi T; Albillos A; Téllez L; Villanueva C; Brujats A; Garcia-Pagan JC; Perez-Campuzano V; Hernández-Gea V; Rautou PE; Moga L; Vanwolleghem T; Kwanten WJ; Francque S; Trebicka J; Gu W; Ferstl PG; Gluud LL; Bendtsen F; Møller S; Kubicek S; Mandorfer M; Reiberger T, 2023. Assessment of portal hypertension severity using machine learning models in patients with compensated cirrhosis. J Hepatol 78(2):390-400
Schwabl P; Seeland BA; Riedl F; Schubert TL; Königshofer P; Brusilovskaya K; Petrenko O; Hofer B; Schiefer AI; Trauner M; Peck-Radosavljevic M; Reiberger T, 2022. Splenectomy ameliorates portal pressure and anemia in animal models of cirrhotic and non-cirrhotic portal hypertension. Adv Med Sci 67(1):154-162
Burghart L; Halilbasic E; Schwabl P; Simbrunner B; Stättermayer AF; Petrenko O; Scheiner B; Bauer D; Pinter M; Boztug K; Mandorfer M; Trauner M; Reiberger T, 2022. Distinct prognostic value of different portal hypertension-associated features in patients with primary biliary cholangitis. J Gastroenterol 57(2):99-110
Königshofer P; Hofer BS; Brusilovskaya K; Simbrunner B; Petrenko O; Wöran K; Herac M; Stift J; Lampichler K; Timelthaler G; Bauer D; Hartl L; Robl B; Sibila M; Podesser BK; Oberhuber G; Schwabl P; Mandorfer M; Trauner M; Reiberger T, 2022. Distinct structural and dynamic components of portal hypertension in different animal models and human liver disease etiologies. Hepatology 75(3):610-622
Königshofer P; Brusilovskaya K; Petrenko O; Hofer BS; Schwabl P; Trauner M; Reiberger T, 2021. Nuclear receptors in liver fibrosis. Biochim Biophys Acta Mol Basis Dis 1867(12):166235
Publication list retrieved from NCBI using ImpactPubs
.